These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 31679914)
1. Risk of Cervical Dysplasia After Colposcopy Care and Risk-Informed Return to Population-Based Screening: A Systematic Review. Costa-Fagbemi M; Yakubu M; Meggetto O; Moffatt J; Walker MJ; Koné AP; Murphy KJ; Kupets R J Obstet Gynaecol Can; 2020 May; 42(5):607-624. PubMed ID: 31679914 [TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804 [TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus test with cytology triage in organized screening for cervical cancer. Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407 [TBL] [Abstract][Full Text] [Related]
4. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study. Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M; Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982 [TBL] [Abstract][Full Text] [Related]
5. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084 [TBL] [Abstract][Full Text] [Related]
6. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population]. Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341 [No Abstract] [Full Text] [Related]
7. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804 [TBL] [Abstract][Full Text] [Related]
8. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241 [TBL] [Abstract][Full Text] [Related]
9. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579 [TBL] [Abstract][Full Text] [Related]
10. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N; J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502 [TBL] [Abstract][Full Text] [Related]
11. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology. Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361 [TBL] [Abstract][Full Text] [Related]
12. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs. Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541 [TBL] [Abstract][Full Text] [Related]
14. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243 [TBL] [Abstract][Full Text] [Related]
15. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222 [TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City]. Zeng X; Li J; Kang LN; Yan LP; He Z; Liao GD; Xi MR; Chen MY Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):896-903. PubMed ID: 36224694 [TBL] [Abstract][Full Text] [Related]
17. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308 [TBL] [Abstract][Full Text] [Related]
18. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886 [TBL] [Abstract][Full Text] [Related]
19. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy. Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948 [TBL] [Abstract][Full Text] [Related]
20. Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test. Kyrgiou M; Kalliala IE; Mitra A; Fotopoulou C; Ghaem-Maghami S; Martin-Hirsch PP; Cruickshank M; Arbyn M; Paraskevaidis E Cochrane Database Syst Rev; 2017 Jan; 1(1):CD009836. PubMed ID: 28125861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]